Bayer - Finerenone - T2DM
Official Title
A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with CKD and T2DM
Study Details
The purpose of this study is to find out if an investigational combination of two drugs is a safe and effective treatment for chronic kidney disease
(CKD) in type 2 diabetes (T2D).
Principal Investigator
Dr. Julie Silverstein
IRB Number
202204183
Eligibility
1. Participants must be at least 18 years old
2. Participants must have type 2 diabetes
3. Participants must have chronic kidney disease
Compensation is provided (contact the study team for compensation amount).
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu